Laura Joszt, MA

Laura Joszt, MA, is the vice president of content for the managed care and pharmacy brands at MJH Life Sciences^®, which includes The American Journal of Managed Care^®, Managed Healthcare Executive®, Pharmacy Times®, and Drug Topics®. She has been with MJH Life Sciences since 2011.

Laura has an MA in business and economic reporting from New York University.

Sandoz Roadmap Aims to Increase Worldwide Biosimilar Adoption by 2030

June 27, 2023

Article

The Act4Biosimilars Action Plan seeks to increase biosimilar adoption by at least 30 percentage points in 30-plus countries by 2030.

Medicare 340B Program May Be Reducing Biosimilar Uptake

June 08, 2023

Article

New research has found the 340B program is slowing uptake of biosimilars by incentivizing use of more expensive biologics.

Employer Playbook Suggests Strategies for Biosimilar Adoption, Navigating Adalimumab Launches

March 09, 2023

Article

A new resource from the National Alliance of Healthcare Purchaser Coalitions aims to help plan sponsors adopt biosimilars into their pharmacy benefit plans.

AJMC: The Top 5 Most Popular Biosimilars Content of 2022

December 27, 2022

Article

The American Journal of Managed Care, a sister site of The Center for Biosimilars, looked back at some of the most popular biosimilars content of 2022 to be published on AJMC.com.

New Phase Will Increase Trajectory of Biosimilar Use in the United States, Expert Says

May 30, 2022

Article

With multiple adalimumab biosimilars poised to enter the market and more biosimilars in more disease states seeking interchangeability, the US market is entering a new phase of biosimilar use.

The US Is Entering Round 2 of Biosimilar Activity, Says Cardinal Health’s Oskouei

May 03, 2022

Article

The United States is about to enter round 2 of biosimilar activity with a pipeline that expands biosimilars into new therapeutic areas, said Sonia Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars, Cardinal Health, during her presentation at Asembia’s Specialty Pharmacy Summit.

Pegfilgrastim Biosimilars Provide Clinical, Economic Benefits to Prevent Febrile Neutropenia

April 18, 2022

Article

An analysis of real-world dosing and effectiveness of pegfilgrastim biosimilars found the clinical benefits of preventing febrile neutropenia in patients with intermediate to high risk come at acceptable financial costs compared with filgrastim biosimilars.

Biosimilar Competition and Utilization Uptake Have Driven Down Costs in the Oncology Space

April 01, 2022

Article

During a session at the Academy of Managed Care Pharmacy annual meeting, Yuqian Liu, PharmD, of Magellan Rx Management, highlighted strategies to encourage biosimilar utilization in the oncology space and the cost savings as a result.

Improved Biosimilar Uptake Saved Health System $26.9M Over 2 Years

March 28, 2022

Article

A series of initiatives to improve uptake of the biosimilars for 7 originator biologics resulted in significant savings for Providence St. Joseph Health.

Hospitals, Physician Offices Significantly Mark Up Prices for 3 Drugs With Biosimilars

February 21, 2022

Article

A report from AHIP found 3 drugs that have multiple biosimilars available can be delivered more affordably through specialty pharmacies.